Search Results - "Riedel, Klaus‐Dieter"
-
1
Trimethoprim–metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
Published in British journal of clinical pharmacology (01-11-2013)“…Aims Metformin pharmacokinetics depends on the presence and activity of membrane‐bound drug transporters and may be affected by transport inhibitors. The aim…”
Get full text
Journal Article -
2
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Published in British journal of clinical pharmacology (01-12-2009)“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pharmacokinetic variability of voriconazole is largely caused by CYP3A4‐ and CYP2C19‐mediated metabolism. • Oral…”
Get full text
Journal Article -
3
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations
Published in PloS one (05-07-2013)“…We evaluated the importance of ethnicity and pharmacogenetic variations in determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in…”
Get full text
Journal Article -
4
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients
Published in PloS one (06-12-2011)“…Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced…”
Get full text
Journal Article -
5
Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry
Published in Analytical and bioanalytical chemistry (01-03-2012)“…The benzodiazepine midazolam is a probe drug used to phenotype cytochrome P450 3A activity. In this situation, effective sedative concentrations are neither…”
Get full text
Journal Article -
6
Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration
Published in Antimicrobial Agents and Chemotherapy (01-06-2010)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
7
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
Published in PloS one (11-07-2012)“…To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug…”
Get full text
Journal Article -
8
Clarithromycin substantially increases steady‐state bosentan exposure in healthy volunteers
Published in British journal of clinical pharmacology (01-01-2014)“…Aims The aim of this study was to assess the effect of the cytochrome P450 (CYP) 3A4 and organic anion‐transporting polypeptide (OATP) 1B1 inhibitor…”
Get full text
Journal Article -
9
Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
Published in British journal of clinical pharmacology (01-11-2012)“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The analgesic activity of tilidine is mediated by its active metabolite, nortilidine, which easily penetrates the…”
Get full text
Journal Article -
10
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Published in Clinical pharmacology and therapeutics (01-08-2006)“…Objectives Cytochrome P450 (CYP) 2C19 and CYP3A4 are the major enzymes responsible for voriconazole elimination. Because the activity of CYP2C19 is under…”
Get full text
Journal Article -
11
The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high‐dose melphalan chemotherapy in patients with multiple myeloma
Published in British journal of clinical pharmacology (01-12-2010)“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Nausea and vomiting are the most distressing side‐effects of a high dose melphalan regimen. • Aprepitant in addition…”
Get full text
Journal Article -
12
Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring
Published in Therapeutic drug monitoring (01-02-2011)“…Very low voriconazole concentrations are commonly observed during therapeutic drug monitoring. Possible mechanisms include inappropriate dose selection, rapid…”
Get full text
Journal Article -
13
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
Published in Clinical pharmacology and therapeutics (01-07-2004)“…Background Ritonavir is a potent in vitro inhibitor of several cytochrome P450 isozymes and ABC transporters including the efflux pump P‐glycoprotein (P‐gp)…”
Get full text
Journal Article -
14
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
Published in Clinical pharmacology and therapeutics (01-07-2005)“…Objectives Constituents of St John's wort (SJW) in vivo induce the cytochrome P450 (CYP) isozymes 3A4, 2C9, and 2C19 but in vitro were shown to inhibit them…”
Get full text
Journal Article -
15
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction
Published in British journal of clinical pharmacology (01-07-2003)“…Aims A clinically important interaction between the cardiac glycoside digoxin and the antibiotic clarithromycin has been suggested in earlier reports. The aim…”
Get full text
Journal Article -
16
Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole
Published in British journal of clinical pharmacology (01-11-2009)“…WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • Tilidine, a World Health Organization level II analgesic, is a high extraction drug subject to pronounced first‐pass…”
Get full text
Journal Article -
17
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40
Published in Clinical pharmacology and therapeutics (01-05-2003)“…Background The pharmacokinetics of digoxin is modulated by the efflux pump P‐glycoprotein. Cremophor EL (BASF Aktiengesellschaft, Ludwigshafen, Germany)…”
Get full text
Journal Article -
18
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine
Published in Malaria journal (08-10-2006)“…The development of safe, effective and affordable drug combinations against malaria in Africa is a public health priority. Methylene blue (MB) has a similar…”
Get full text
Journal Article -
19
Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (01-03-2008)“…Selective and sensitive methods for the determination of the cationic dye and anti-malarial methylene blue in human liquid whole blood, dried whole blood…”
Get full text
Journal Article -
20
Undeclared exposure to St. John's Wort in hospitalized patients
Published in British journal of clinical pharmacology (01-10-2004)“…Aim The herbal medicine St. John's Wort (SJW) causes substantial decreases in the plasma concentrations of a range of co‐administered drugs. Therefore, we…”
Get full text
Journal Article